Detalles de la búsqueda
1.
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
J Med Genet
; 2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37940383
2.
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Genet Med
; 25(12): 100968, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37634127
3.
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial.
J Clin Gastroenterol
; 55(2): 134-140, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32501868
4.
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Blood Cells Mol Dis
; 82: 102418, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32146279
5.
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Blood Cells Mol Dis
; 78: 14-21, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27499018
6.
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
J Inherit Metab Dis
; 42(3): 534-544, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30834538
7.
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Blood Cells Mol Dis
; 68: 163-172, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27839981
8.
Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa.
J Inherit Metab Dis
; 41(6): 1259-1265, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30066229
9.
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Am J Hematol
; 91(7): 661-5, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27102949
10.
Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
Am J Hematol
; 91(7): 656-60, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27174694
11.
Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
Blood Cells Mol Dis
; 54(1): 9-16, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25453586
12.
Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R.
Toxicol Appl Pharmacol
; 287(3): 202-9, 2015 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26051873
13.
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Blood Cells Mol Dis
; 53(4): 253-60, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24950666
14.
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
Blood
; 118(22): 5767-73, 2011 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21900191
15.
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Orphanet J Rare Dis
; 18(1): 332, 2023 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37865771
16.
Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model.
Blood Cells Mol Dis
; 46(1): 47-52, 2011 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21084202
17.
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story.
PLoS One
; 12(10): e0186211, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29088235
18.
An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy.
J Immunol Methods
; 446: 21-29, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28392436
19.
Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
PLoS One
; 10(6): e0128986, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26053270
20.
Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience
Artículo
en Inglés
| ARCA | ID: arc-32443